CLINICAL TRIAL / NCT06423911

Study of Olverembatinib (HQP1351) in Patients With CP-CML

  • Interventional
  • Recruiting
  • NCT06423911

This is a Global, Multi-center, Open-label Randomized and Registrational Phase 3 Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia

A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)